Anti-DcR2 抗体 (ab2019)

Submit a review Q&A (2)References (10)
Western blot - Anti-DcR2 antibody (ab2019)
  • Immunocytochemistry - Anti-DcR2 antibody (ab2019)

Key features and details

  • Rabbit polyclonal to DcR2
  • Suitable for: ICC, WB
  • Reacts with: Human
  • Isotype: IgG

製品の概要

  • 製品名

    Anti-DcR2 antibody
    DcR2 一次抗体 製品一覧

  • 製品の詳細

    Rabbit polyclonal to DcR2

  • 由来種

    Rabbit

  • 特異性

    Human, Mouse, Rat

  • アプリケーション

    適用あり: ICC, WBmore details

  • 種交差性

    交差種: Human

  • 免疫原

    Synthetic peptide corresponding to Human DcR2 aa 249-263.
    Sequence:

    GGPERVHRVLFRRRS


    (Peptide available as ab8379)
    Run BLAST with BLAST the sequence with ExPASy Run BLAST with BLAST the sequence with NCBI

  • 特記事項

    Decoy Receptor 2 for TRAIL

    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.

    If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As

製品の特性

アプリケーション

The Abpromise guarantee

Abpromise保証は、 次のテスト済みアプリケーションにおけるab2019の使用に適用されます

アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。

アプリケーション Abreviews 特記事項
ICC
Use a concentration of 10 µg/ml.
WB
1/1000 - 1/2000.
特記事項
ICC
Use a concentration of 10 µg/ml.
WB
1/1000 - 1/2000.

ターゲット情報

  • 機能

    Receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis. Reports are contradictory with regards to its ability to induce the NF-kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway.

  • 組織特異性

    Widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. Also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart.

  • 配列類似性

    Contains 1 death domain.
    Contains 3 TNFR-Cys repeats.

  • 細胞内局在

    Membrane.
  • Information by UniProt

  • 参照データベース

    • 別名

      • CD 264 antibody
      • CD264 antibody
      • DcR 2 antibody
      • DcR2 antibody
      • Decoy receptor 2 antibody
      • Decoy with truncated death domain antibody
      • OTTHUMP00000123528 antibody
      • TNF receptor related receptor for TRAIL antibody
      • TNF related apoptosis inducing ligand receptor 4 antibody
      • TNF-related apoptosis-inducing ligand receptor 4 antibody
      • TNFRSF 10D antibody
      • TNFRSF10D antibody
      • TR10D_HUMAN antibody
      • TRAIL R4 antibody
      • TRAIL receptor 4 antibody
      • TRAIL receptor with a truncated death domain antibody
      • TRAIL-R4 antibody
      • TRAILR4 antibody
      • TRUNDD antibody
      • Tumor necrosis factor receptor superfamily member 10D antibody
      • Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain antibody
      see all

    画像

    • Western blot - Anti-DcR2 antibody (ab2019)
      Western blot - Anti-DcR2 antibody (ab2019)
      Anti-DcR2 antibody (ab2019) at 1/1000 dilution + HeLa whole cell lysate

      Observed band size: 35 kDa why is the actual band size different from the predicted?

    • Immunocytochemistry - Anti-DcR2 antibody (ab2019)
      Immunocytochemistry - Anti-DcR2 antibody (ab2019)

      ab2019 at 10µg/ml staining DcR2 in human Hela cells by Immunocytochemistry.

    参考文献 (10)

    ab2019 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

    ab2019 は 10 報の論文で使用されています。

    • Wang Z  et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduct Target Ther 5:40 (2020). PubMed: 32327638
    • Brunetti G  et al. High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. Oncol Rep 39:2031-2039 (2018). PubMed: 29484421
    • You C  et al. ß-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors. Int J Oncol 53:2258-2268 (2018). PubMed: 30132512
    • Chung SI  et al. Comparison of liver oncogenic potential among human RAS isoforms. Oncotarget 7:7354-66 (2016). PubMed: 26799184
    • Laine A  et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 3:182-97 (2013). Human . PubMed: 23306062
    • Yu M  et al. Inactivation of TGF-ß signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene N/A:N/A (2013). Mouse . PubMed: 23604118
    • Fan LC  et al. a-Catulin knockdown induces senescence in cancer cells. Oncogene 30:2610-21 (2011). WB . PubMed: 21278790
    • Anees M  et al. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117:1172-82 (2011). PubMed: 21381010
    • Emblom-Callahan MC  et al. Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 96:134-45 (2010). WB ; Human . PubMed: 20451601
    • Leithner K  et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 65:98-104 (2009). PubMed: 19081160

    レビューと Q&A

    Show All レビュー Q&A
    レビューを送る 質問を送る

    1-2 of 2 Abreviews or Q&A

    Question

    Kreuzreaktivität dieser Antikörper?

    Read More
    Answer

    Vielen Dank für Ihren Anruf.
    Ich habe nachgefragt ob und wie die Spezifität der folgenden Antikörper getestet wurde:
    ab108421:
    Dieser Antikörper wurde nicht experimentell auf die Kreuzreaktion mit anderen Trail Rezeptoren getestet. Ich kann allerding bestätigen, dass das Immunogen keine signifikante Homologie mit DcR1 und DcR3 aufweist. Wir können dies allerdings nicht garantieren.
    ab2019:
    Dieser Antikörper wurde ebenfalls nicht experimentell auf die Kreuzreaktion mit anderen Trail Rezeptoren getestet. Ich kann allerding bestätigen, dass nach einer BLAST-Suche das Immunogen keine signifikante Homologie mit anderen Trail Rezeptoren aufweist. Wir können dies allerdings nicht garantieren.
    ab14738:
    Die Kreuzreaktivität dieses Antikörpers wurde mittels TRAIL-R2 transfizierten Zellen ausgeschlossen. Es wurden außerdem Zelllinien, die TRAIL-R3 and TRAIL-R4 exprimieren verwendet und so eine Kreuzreaktion ausgeschlossen.
    Ich hoffe, diese Information ist hilfreich. Bitte zögern Sie nicht sich nochmals zu melden, falls Sie weitere Fragen haben.

    Read More

    Question

    The following article   Leithner K et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 65:98-104 (2009). PubMed: 19081160   appears in the references list of ab2019 and according to the images of IHC-P in this article the customer ordered it. In addition to this, the customer is interested in purchasing of Anti-DcR1 that was also used in this article and its IHC-P staining also appear in this article. Unfortunately, no catalog numbers are indicated in the article and in abcam's website not even one Anti-DcR1 antibody is guaranteed for IHC-P of human sections.    Kindly advise and assist with the finding of this particular Anti-DcR1 that was used in the article.  

    Read More
    Answer

    Unfortunately I could not find in our system any order related to DcR1 and this Austrian research group. I would suggest your customer to contact directly the authors of this publication. Sorry I cannot be more helpful on this occasion.

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com